期刊文献+

非小细胞肺癌中PD-L1的表达及其与临床病理特征的关系 被引量:7

Expression of PD-L1 in non-small-cell lung cancer and its correlation with clinicopathological characteristics
下载PDF
导出
摘要 目的探究非小细胞肺癌(non-small-cell lung cancer,NSCLC)中程序性死亡配体1(programmed death-ligand 1,PDL1)的表达情况及其与患者临床病理特征之间的关系。方法采用免疫组织化学检测107例NSCLC组织中的PD-L1表达,结合临床资料分析PD-L1表达和临床病理特征的关系。利用癌症基因组图谱(The Cancer Genome Atlas,TCGA)数据库里的NSCLC数据分析肿瘤组织和癌旁组织中PD-L1 mRNA表达差异。结果107例NSCLC中,肺腺癌74例,肺鳞癌33例。肺腺癌和肺鳞癌组织中PD-L1的表达阳性率分别为18.9%(14/74)和57.6%(19/33)。生物信息学分析表明,与癌旁组织比较,PD-L1在肺腺癌中表达发生下调(logFC=-0.703,P<0.01),而在肺鳞癌中PD-L1差异无统计学意义(P=0.078)。74例肺腺癌患者的PD-L1表达在T分期(χ^(2)=8.955,P=0.011)和TNM分期(χ^(2)=6.166,P=0.046)方面比较,差异均具有统计学意义,而33例肺鳞癌患者的PD-L1表达在N分期(χ^(2)=3.860,P=0.049)和TNM分期(χ^(2)=7.649,P=0.022)方面比较,差异均具有统计学意义。结论肺鳞癌中PD-L1表达阳性率高于肺腺癌。在2种不同的NSCLC亚型中PD-L1表达水平在不同TNM分期中有差异。 Objective To explore the expression of programmed death-ligand 1(PD-L1)in non-small-cell lung cancer(NSCLC)and its correlation with the clinicopathological characteristics of patients.Methods Immunohistochemistry was used to detect the expression of PD-L1 in 107 NSCLC tissues,and the relationship between PD-L1 expression and clinicopathological characteristics was analyzed based on the clinical data.The NSCLC data in The Cancer Genome Atlas(TCGA)database were used to analyze the difference of PD-L1 mRNA expression in tumor tissues and adjacent tissues.Results Among the 107 NSCLC cases,74 cases were lung adenocarcinoma and 33 were lung squamous cell carcinoma.The positive rates of PD-L1 expression in lung adenocarcinoma and lung squamous cell carcinoma were 18.9%(14/74)and 57.6%(19/33),respectively.Bioinformatics analysis showed that PD-L1 expression was down-regulated in lung adenocarcinoma compared with adjacent tissues(logFC=-0.703,P<0.01),but there was no statistically significant difference in the change of PD-L1 in lung squamous cell carcinoma(P=0.078).Combined with the clinicopathological data,the PD-L1 expression in lung adenocarcinoma was compared in terms of T stage(χ^(2)=8.955,P=0.011)and TNM stage(χ^(2)=6.166,P=0.046),and the difference was statistically significant.The PD-L1 expression in lung squamous cell carcinoma was compared in terms of N stage(χ^(2)=3.860,P=0.049)and TNM stage(χ^(2)=7.649,P=0.022),and the difference was statistically significant.Conclusions The positive rate of PD-L1 expression in lung squamous cell carcinoma is higher than that in lung adenocarcinoma.The PD-L1 expression level in both subtypes of NSCLC is different in terms of TNM stage.
作者 游星兰 任建敏 毛卫波 黄建胜 You Xinglan;Ren Jianmin;Mao Weibo;Huang Jiansheng(Department of Clinical Laboratory,Lishui Central Hospital,Lishui 323000,China;Department of Pathology,Lishui Central Hospital,Lishui 323000,China)
出处 《实用肿瘤杂志》 CAS 2021年第6期520-524,共5页 Journal of Practical Oncology
基金 浙江省自然科学基金(LY18H160059) 浙江省自然科学青年基金(LQ17H080001)。
关键词 非小细胞肺癌 肺腺癌 肺鳞癌 程序性死亡配体1 non-small-cell lung cancer lung adenocarcinoma lung squamous cell carcinoma programmed death-ligand 1
  • 相关文献

参考文献5

二级参考文献37

  • 1Siegel R, Naishadham D, Jemal A. Cancer statistic, 2012 [J]. CA Cancer J Clin,2012,62(1) :10 -29.
  • 2Ettinger DS, Akerley W, Bepler G, et al. Non-small cell lung cancer[J]. J Natl Compr Canc Netw,2010,8 (7) : 740 - 801.
  • 3Pikor LA, Ramnarine VR, Lam Stephen, et al. Genetic alterations defining NSCLC subtypes and their therapeutic implications[ J]. Lung Cancer,2013,82(2) :179 - 189.
  • 4Hainsworth JD, Fang L, Huang JE, et al. BRIDGE: an open-label phase II trial evaluating the safety of bevaci- zumab + carboplatin/paclitaxel as first-line treatment for patients with advanced previously untreated, squamous non-small cell lung cancer [J]. J Thorac Oncol, 2011,6 (1) :109 -114.
  • 5Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or earboplatin-paclitaxel in pulmonary adenoearcinoma [ J ]. N Engl J Med,2009,361 (10) :947 -957.
  • 6Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer [J]. N Engl J Med,2010,363(18) :1693 - 1703.
  • 7Gandhi L, Janne PA. Crizotinib for ALK-rearranged non- small cell lung cancer: a new targeted therapy for a new target[ J ]. Clin Cancer Res ,2012,18 ( 14 ) :3737 - 3742.
  • 8Pikor LA, Ramnarine VR, Lam S, et al. Genetic alterations defining NSCLC subtypes and their therapeutic implica- tions [ J ]. Lung Cancer, 2013,82 ( 2 ) : 179 - 189.
  • 9Kris MG,Johnson BE, Berry LD,et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs [ J ]. JAMA, 2014,311 (19) : 1998 - 2006.
  • 10Barlesi F, Blons H, Beau-Failer M, et al. Biomarkers(BM) France : Results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EMIA-ALK gene fusion assessment on the first 10,000 non-small cell lung cancer (NSCLC) patients (pts) [J]. J Clin Onco1,2013,31 (suppl) : abstr 8000.

共引文献92

同被引文献57

引证文献7

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部